MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MEN-1703’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEN-1703 is under development for the treatment of acute myeloid leukemia (newly diagnosed), relapsed and refractory acute myeloid leukemia (AML), diffuse large B-cell lymphoma and multiple myeloma (kahler's disease) and Hodgkin lymphoma. The drug candidate is administered through oral route and formulated as capsule. It acts by targeting both PIM kinase and FLT3. It was also under development for chronic myelocytic leukemia, solid tumors, chronic lymphocytic leukemia.
Stemline Therapeutics overview
Stemline Therapeutics (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprises of SL-401, SL-701, SL-801, SL-501 and SL-101. Stemline’s SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of hematologic cancers. The company’s SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Its SL-801 is a novel oral small molecule reversible inhibitor of Exportin-1. Stemline is headquartered in New York, the US.
For a complete picture of MEN-1703’s drug-specific PTSR and LoA scores, buy the report here.